From the American Academy of Ophthalmology

This retrospective study evaluated the efficacy of anti-VEGF therapy in 91 patients with wet AMD accompanied by submacular hemorrhage. At six months, visual acuity in most patients improved or remained stable. However, efficacy in eyes with large hemorrhage was limited, suggesting the need for more aggressive treatment in these cases. Longer duration of symptoms, greater extent of hemorrhage and greater central foveal thickness at diagnosis correlated with worse visual outcomes at six months. No difference in visual acuity outcome between typical exudative AMD and polypoidal choroidal vasculopathy was identified. Ophthalmology, April 2014